Can Ozempic, Wegovy, Mounjaro or Zepbound Affect Your Eyes?

Semaglutide is the active medication in Ozempic®, Wegovy® and Rybelsus®. Tirzepatide is the active medication in Mounjaro® and Zepbound® and acts on both GIP and GLP-1 receptors. These medicines can produce major benefits for diabetes, obesity and cardiovascular risk in appropriately selected patients. Their eye risks should be put in context rather than described with blanket phrases such as “Ozempic blindness.”

It can be associated with a temporary worsening of diabetic retinopathy, particularly when a person already has diabetic retinopathy and blood glucose improves quickly. This “early worsening” phenomenon has been recognized with intensive diabetes treatment for decades, and it is not the same as proving that semaglutide is directly toxic to the retina.

Non-arteritic anterior ischemic optic neuropathy (NAION) is an uncommon condition in which part of the optic nerve is injured after insufficient blood supply. It usually produces sudden, painless vision loss in one eye. Patients may notice a dark or gray area, dim vision, or a missing upper or lower portion of the visual field. Our neuro-ophthalmology pages cover optic-nerve conditions in more detail.

Several large observational studies have reported more NAION among semaglutide users. A Danish nationwide study of 424,152 people with type 2 diabetes found a hazard ratio of 2.19. A Danish–Norwegian study found a pooled hazard ratio of 2.81 and an absolute excess of about 1.41 cases per 10,000 person-years. These studies cannot completely eliminate confounding, because diabetes, sleep apnea and vascular disease themselves increase NAION risk.

The 2026 joint consensus statement from the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology treats the signal seriously but emphasizes that the overall magnitude of the risk remains low and that the evidence comes from retrospective observational studies with real limitations. It calls for shared decision-making between each patient and their care team about whether to start, continue or stop a GLP-1 medication, weighing the medication’s systemic benefits against the individual’s ocular risk.

The evidence is also not uniform. A 2026 systematic review of six observational studies found that, after adjustment, the pooled estimates did not show a consistent overall increase in NAION, with low to very low certainty — a reminder that the question is still being studied, and that an association is not the same as proof of cause.

No. The strongest current NAION evidence is for semaglutide. Tirzepatide has appeared in observational datasets and case reports, but it should not be presented as having the same proven risk, and the evidence for it is thinner in either direction. Tirzepatide’s U.S. labeling does warn that rapid improvement in glucose control can temporarily worsen diabetic retinopathy in susceptible patients. The evidence should be stated drug by drug whenever possible.

• People with significant pre-existing diabetic retinopathy, especially when very high blood sugar is expected to improve rapidly.
• People who have already had NAION in one eye.
• People with common NAION risk factors such as diabetes, obstructive sleep apnea, hypertension or other vascular risk factors, nocturnal hypotension, or a small, “crowded” optic nerve.
• Anyone who develops a new, unexplained visual-field defect, sudden dimming, or painless loss of vision.

Yes, sometimes indirectly. Large and rapid changes in blood glucose can temporarily change the focusing power of the natural lens inside the eye. That can cause a short-term refractive shift and blurry vision. Persistent blur should not simply be blamed on the medication, because diabetic macular edema, cataract, retinal vascular disease, optic neuropathy and other eye conditions can also reduce vision.

Do not stop an otherwise beneficial medication simply because you read that it can affect the eyes. If NAION is suspected or confirmed, the ophthalmologist and the prescribing clinician should communicate promptly. European semaglutide product information advises stopping semaglutide when NAION is confirmed. U.S. labeling and specialty-society guidance should be checked at the time of treatment, because regulatory language can change.

Semaglutide and tirzepatide delay stomach emptying. Current U.S. labels report rare cases of pulmonary aspiration during general anesthesia or deep sedation in patients who had residual stomach contents despite reporting that they had followed fasting instructions. If you take one of these medicines, tell the surgical and anesthesia team before any procedure, including cataract surgery. Do not stop the medication on your own; follow the individualized instructions from the team managing your procedure.